Clinical data
Routes of
Oral, sublingual
Legal status
Legal status
Pharmacokinetic data
Bioavailability ?
Metabolism Hepatic
Biological half-life ~42 hours[1]
Excretion Renal
CAS Number 2894-68-0 YesY
PubChem (CID) 76168
ChemSpider 68652
Chemical and physical data
Formula C16H12Cl2N2O
Molar mass 319.185 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Diclazepam (Ro5-3448), also known as chlorodiazepam and 2'-chloro-diazepam, is a benzodiazepine designer drug and functional analog of diazepam. It was first synthesized by Leo Sternbach and his team at Hoffman-La Roche in 1960.[2] It is not currently approved for use as a medication, but rather sold as a designer drug.[3][4] Efficacy and safety have not been tested in humans.

In animal models, its effects are similar to diazepam, possessing long-acting anxiolytic, anticonvulsant, hypnotic, sedative, skeletal muscle relaxant, and amnestic properties.


Metabolism of this compound has been assessed,[1] revealing diclazepam has an approximate elimination half-life of 42 hours and undergoes N-demethylation to delorazepam, which can be detected in urine for 6 days following administration of the parent compound.[5] Other metabolites detected were lorazepam and lormetazepam which were detectable in urine for 19 and 11 days, respectively, indicating hydroxylation by cytochrome P450 enzymes occurring concurrently with N-demethylation. The protein-binding of this compound has not been analysed but the figures for the metabolites are, delorazepam >90%,[6] lorazepam 91.5% (parenterally) & 85% (orally)[7] and delorazepam >90%.[6]

See also


  1. 1 2 Moosmann B, Bisel P, Auwärter V (July–August 2014). "Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics". Drug Testing and Analysis. 6 (7-8): 757–63. doi:10.1002/dta.1628. PMID 24604775.
  2. US 3136815, "Amino substituted benzophenone oximes and derivatives thereof"
  3. Madeleine Pettersson Bergstrand; Anders Helander; Therese Hansson; Olof Beck (2016). "Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays". Drug Testing and Analysis. doi:10.1002/dta.2003. PMID 27366870.
  4. Høiseth, Gudrun; Tuv, Silja Skogstad; Karinen, Ritva (2016). "Blood concentrations of new designer benzodiazepines in forensic cases". Forensic Science International. doi:10.1016/j.forsciint.2016.09.006.
  5. Bareggi SR, Truci G, Leva S, Zecca L, Pirola R, Smirne S (1988). "Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans". European Journal of Clinical Pharmacology. 34 (1): 109–112. doi:10.1007/bf01061430. PMID 2896126.
  6. 1 2 http://www.drugbank.ca/drugs/DB01511
  7. http://www.drugbank.ca/drugs/DB00186
This article is issued from Wikipedia - version of the 9/18/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.